Henry Schein Stock Falls on Q2 Earnings Miss, Revenues Top

Henry Schein (HSIC) reported Q2 2025 adjusted EPS of $1.10, missing analyst estimates by 6.8% and declining 10.6% year-over-year, which prompted a 4.7% pre-market stock drop. Despite the earnings miss, net sales increased 3.2% to $3.24 billion, surpassing expectations, largely supported by robust growth in Technology, Specialty, and Global Medical Distribution segments. However, the company experienced margin contraction, with gross margin narrowing by 110 basis points and adjusted operating margin by 21 basis points, though it reiterated its full-year 2025 adjusted EPS and revenue guidance.

Analysis

Henry Schein (HSIC) reported a dichotomous second quarter, characterized by a revenue beat but a significant earnings miss that drove a 4.7% pre-market stock decline. Net sales grew 3.2% year-over-year to $3.24 billion, surpassing consensus estimates, fueled by strong performance in its Global Technology (+7.4%) and Global Specialty Products (+4.2%) segments. However, this top-line strength was undermined by considerable margin pressure; the gross margin contracted 110 basis points and the adjusted operating margin fell 21 basis points, leading to a 10.6% year-over-year drop in adjusted EPS to $1.10, which was 6.8% below expectations. Key operational weaknesses included a 0.4% constant currency decline in Global Dental Distribution merchandise sales and lower US dental equipment sales attributed to tariff-related uncertainty. A significant red flag is the sharp decline in cumulative net cash from operating activities to $157 million from $493 million in the prior-year period, which raises questions about working capital management, especially as the company executed a $259 million share repurchase. Despite these headwinds, management maintained its full-year 2025 guidance for both revenue (2-4% growth) and adjusted EPS ($4.80-$4.94), signaling confidence that the margin and segment-specific issues are manageable.

Key Decisions for Investors

• Given the reiterated full-year guidance, the post-earnings dip could present an opportunity, but investors must weigh this against the significant margin compression and the 10.6% year-over-year EPS decline.
• The sharp drop in cash from operations from $493 million to $157 million is a critical concern that requires scrutiny, as it questions the quality of earnings and the sustainability of the aggressive share repurchase program.
• Monitor performance in the core Global Dental Distribution segment and cost of sales trends in the upcoming quarters, as a recovery in these areas is crucial for the company to meet its unchanged annual targets.
• Investors should assess whether the high-growth contributions from the Technology and Specialty Products segments are sufficient to offset the persistent margin and volume pressures in the larger, core distribution business.